S-1, A NOVEL ORAL FLUOROPYRIMIDINE, WHEN COMBINED WITH CISPLATIN, DEMONSTRATES SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL OF ADVANCED GASTRIC CANCER PATIENTS OVER S-1 ALONE
Contact:Sanofi-aventis Taiho PharmaceuticalAnne BANCILLON Atsushi AZUMA+ 33 6 86 31 03 89 + 81-3-3294-4524EMBARGOED until June 3, 20075:00 PM (Chicago Time) – 24:00 (Paris Time)S-1, A NOVEL ORAL FLUOROPYRIMIDINE,WHEN COMBINED WITH CISPLATIN, DEMONSTRATES SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL OF ADVANCED GASTRIC CANCER PATIENTS OVER S-1 ALONE- Positive results of the “SPIRITS” Study Reportedin Oral Presentation at ASCO 2007 -Chicago, IL, Tokyo, Japan, Paris, France, June 3, 2007- Taiho and sanofi-aventis announced today the results of a phase III trial in advanced